Back to results
US 2023/0054941 A1Published application
Inhibition of dennd5b expression for treating hepatic steatosis
AssigneeUniversity of Kentucky Research Foundation
InventorScott Gordon
Life of this patent
Estimating the term…
Abstract
Methods of treating hepatic steatosis involve administering to a subject a DENND5B inhibitor, thereby reducing the expression of and/or activity of DENND5B in liver of the subject. The DENND5B inhibitor can include antisense oligonucleotide (ASO), CRISPR interference (CRISPRi), miRNA, siRNA, locked nucleic acid (LNA) nucleotides, or a combination thereof.
Claims12
A method of treating hepatic steatosis, comprising:
- identifying a subject having or at risk of developing hepatic steatosis, and
- administering to the subject a DENND5B inhibitor, thereby reducing the expression of and/or activity of DENND5B in the subject.
Dependencies are inferred from the claim text.